[one week king] the two sessions are hot. Why does the disharmonious picture of the pharmaceutical industry reappear?

This week was dominated by the NPC and CPPCC As we are in the pharmaceutical industry, we are even more worried about this week We listened carefully to every word of Representatives, chewed and analyzed every word, lest we miss or misunderstand every new deal So what messages did the delegates give us in the meantime? 1 What are the hot topics in the pharmaceutical industry of the two sessions this year? On March 4, 12 members of the National People's Congress of the people's Republic of China (CPPCC) held the "2017 ninth 'voice responsibility' Forum of CPPCC members of the National People's Congress of the pharmaceutical industry" by 25 associations (Academic) of the Chinese pharmaceutical industry such as China Pharmaceutical Enterprise Management Association, and more than 40 representatives of the National People's Congress and CPPCC members from the pharmaceutical industry attended the forum The members of the committee spoke freely about the key and difficult issues of the current medical system reform and put forward many targeted opinions and suggestions According to incomplete statistics, last year, the proposals and proposals related to the pharmaceutical industry submitted by the representatives of the national "two sessions" received more than 200 replies from the national development and Reform Commission, the health and Family Planning Commission, the Ministry of human resources and social security, the Ministry of Commerce, the state food and Drug Administration and other relevant departments 2 Li Keqiang is the strongest voice of the two sessions of the National People's Congress of the people's Republic of China The four-year changes in key medical and health work at 9 a.m on March 5, 2017, the fifth session of the 12th National People's Congress opened, and Premier Li Keqiang made the fourth report on the work of the government during his term of office This report clearly lists "promoting healthy China Construction" as the key work in 2017 Looking back on Premier Li Keqiang's four government work reports so far, the key work deployment for medical and health care has attracted much attention every year The core contents of each year are different from "promoting medical reform to in-depth development" in 2014, "accelerating the improvement of basic medical and health system" in 2015, "coordinating the promotion of medical, medical insurance and pharmaceutical linkage reform" in 2016, and "promoting the construction of a healthy China" in 2017 By reviewing, combing and comparing, we may have a deeper understanding of the reform of the medical and health system 3 Bi Jingquan explained in detail why the new drugs are slower to be listed at home than abroad on the morning of March 5 In an interview with the "two sessions minister channel" in the Great Hall of the people, Bi Jingquan, director of the State Food and drug administration, said that the low number of drug approval centers of the administration is one of the main reasons for the slow listing of new drugs At present, the domestic drug approval is slow, leading to the domestic market later than the foreign market Minister Bi raised four reasons for this, which have institutional problems 4 After taking the reassuring pill, the researchers only need to "work hard" to "let the researchers no longer distract themselves from the trivial things." The clear statement in this year's government work report has given researchers a reassurance This means that in the future, all you need to do is roll up your sleeves and do the work No other energy is involved There is no enthusiasm for achievement transformation, single talent evaluation mechanism, and dogma of project funds management In recent years, these problems have become the obstacle to the innovation of scientific researchers, and become one of the hot topics discussed by the representatives of the two sessions of the National People's Congress every year What's exciting is that the government has taken concrete measures every year to release the innovation vitality of scientific researchers This year's report on the work of the government has released "big moves" When the two sessions were in full swing, the disharmonious side could not be controlled after all Recently, many drugs were checked, punished and sealed The supervision of food and drug has never been relaxed, but the illegal production and sale of drugs are not allowed For details, please refer to the following: 1 Circular of the General Administration on the disqualification of 23 batches of Chinese Herbal Pieces According to the inspection of Hebei Pharmaceutical Inspection and Research Institute, it is marked as Hebei Liankang Pharmaceutical Co., Ltd., Nanjing Haiyuan Herbal Pieces Co., Ltd., Anhui jinfurong Herbal Pieces Co., Ltd., Jiangxi qingkangyuan Herbal Pieces Co., Ltd., Zhangshu Qingren Herbal Pieces Co., Ltd., Shandong juancheng Zhiyuan Herbal Pieces Co., Ltd., Henan qianfang Pharmaceutical Co., Ltd., Yuzhou Kaixuan Pharmaceutical Co., Ltd., Yuzhou Jindi Herbal Pieces Co., Ltd., Hubei Shennong Bencao Herbal Pieces Co., Ltd., Hunan Futai Herbal Pieces Co., Ltd., Shaoyang Shennong herbal science and Technology Development Co., Ltd., Guangxi Guigang Shennong Pharmaceutical Co., Ltd., Sichuan Jingcheng Herbal Pieces Co., Ltd., Gansu guocao Pharmaceutical Co., Ltd., Gansu hot spring Biotechnology Co., Ltd The 23 batches of Forsythia produced by the limited liability company and Qinghai jiukang Herbal Pieces Co., Ltd are unqualified Unqualified items include content determination, leachables, impurities, etc 2 Drug inspection, many drug dealers, drugstores were checked! Case 1: on March 5, the reporter learned from the State Food and drug administration that the five batches (batch number: 20160109, 20160407, 20160613, 20150113, 20151212) of xiweipei pills and one batch of Huoxiang Qushu soft capsule produced by Shanxi Huanghe traditional Chinese Medicine Co., Ltd marked as Tibet Shenhou Pharmaceutical Co., Ltd were unqualified Case 2: Recently, Xiamen food and drug quality inspection and Research Institute supervised and sampled the drug quality of drug manufacturers, distributors and users in Xiamen, and found that 43 batches of drugs did not meet the standards Among them, the unqualified products include Huoxiang Zhengqi water, Banlangen, Xiangsha Liujun pill and compound Danshen tablets, which are commonly used over-the-counter drugs by Xiamen citizens Case 3: Hefei food and drug administration supervises and samples the aloes prepared by Hefei lejialaopu traditional Chinese medicine Yinpian Co., Ltd sold by Hefei pharmacy chain Co., Ltd of Nanjing medicine After being inspected by Guangdong food and Drug Inspection Institute, its properties, identification and inspection items do not conform to the standards According to the law, the above aloes are identified as fake drugs, and the value of the counterfeit drugs involved is 4 More than ten thousand yuan Case 4: "xiangdanqing" brand Keyan capsule, which is sold by Nanjing Pharmaceutical Hefei pharmacy chain Co., Ltd (Haizhou pharmacy, Renhetang pharmacy), Hefei Ruihui pharmacy, and Yaohai District Xinya pharmacy, is a counterfeit product with the production license No of Xi'an Yangjian Pharmaceutical Co., Ltd as Shaanxi food and Drug Administration s20140006 3 In order to ensure that the content of Geniposide in the finished product of Qingre Jiedu tablet meets the quality standard, the enterprise added Geniposide in the semi-finished product of Qingre Jiedu tablet without authorization In addition, the General Administration also found that the management of enterprise records was disordered The quality authorized person and the manager's office of the production department all stored the batch production records of 2015 and 2016 heat clearing and detoxification tablets, without the finished product release form; the production management was disordered, and the dismantled waste production equipment was stacked in the aisle of the pretreatment workshop and the processing workshop Before leaving, the GMP certificate was received, leaving the words: further investigation and treatment of the enterprise In a flash, the pharmaceutical market is still booming Who enters the pharmaceutical industry? Which company finally went public? Whose report card is brilliant? Now Xiaobian will watch with you 1 Shunfeng enters the Bureau The battle of pharmaceutical distribution is about to break out The fast speed and many outlets are the advantages What's more, the mode is overturned In the past, large-scale commercial distribution used to charge distribution fees according to several points The more expensive the medicine is, the higher the distribution fee will be For example, if a box of medicine costs 10000 yuan and 5 points are charged, the distribution fee will reach 500 yuan 2 Another 18 pharmaceutical companies are listed! According to the statistics of relevant data, in February 2017, there were 18 pharmaceutical enterprises listed on the market Among them, in addition to the listing of Kangtai bio on the Shenzhen growth enterprise board, the other 17 pharmaceutical enterprises are listed on the new third board, including tianzhang Co., Ltd., Pengyang Pharmaceutical Co., Ltd., Penghai Pharmaceutical Co., Ltd., etc In terms of regions, Guangdong Province and Jiangsu Province have the most enterprises on the list, with 4 enterprises respectively, followed by Zhejiang Province, Hubei Province and Hebei Province, with 2 enterprises each 3 14 listed pharmaceutical companies released 2016 "report card", with the highest revenue of 14.127 billion! According to incomplete statistics, as of 19:00 on March 3, a total of 14 companies in the pharmaceutical sector published their 2016 annual results Harbin Pharmaceutical Co., Ltd ranks first in terms of revenue, reaching 14 billion 127 million yuan It is also the only company with revenue exceeding 10 billion yuan In addition, there are four companies with a revenue of more than 2 billion yuan, which are Yixintang (6.249 billion), Enhua Pharmaceutical (3.018 billion), Qianjin Pharmaceutical (2.865 billion) and Tomson Beijian (2.309 billion) 4 The third grade a hospital is angry: stop medicine, do not pay money, take medicine instead! On March 6, the Discipline Inspection Commission of Lishui people's Hospital of Zhejiang Province issued a notice (see the annex for details): on February 28, the Discipline Inspection Commission of the hospital organized the supervision office, the security department, the pharmaceutical department, etc to inspect the medical representatives' access to the ward's diagnosis area, and found that there was a suspected drug agent diagnosis area on the second floor of the outpatient clinic After understanding and monitoring, it is confirmed that this person is the medical representative of a pharmaceutical company, and it is in the hospital on February 28 to promote drugs Therefore, the hospital department of Lishui people's hospital decided to stop the drug or stop paying for the drug At the same time, if the hospital warns the drug companies that don't take over, the punishment will be more severe in the future; the hospital will increase the intensity of the inspection, with only one purpose: the hospital's diagnosis area and ward area, to prevent the emergence of drug substitution - resolute attitude, tough tone, through the announcement, it seems that the hospital can feel the "activities" of the drug companies in the hospital, zero tolerance Original statement: This article is the integration of yaozhi.com, welcome to reprint, reprint please indicate the source and author, thank you!